Abstract
The neuroprotection of acute ischemic stroke (AIS) patients to alleviate reperfusion injury is a long-standing challenge. While intra-arterial selective cooling saline infusion (IA-SCSI) is a promising technique, clinical results have been inconsistent. Magnesium sulfate ($MgSO_4$) protects cells by modulating intracellular $Ca^{2+}$ content, suggesting its potential as a hypothermia infusion solution. This study hypothesized that $MgSO_4$, as a novel hypothermia infusion solution (IA-SCMI), can promote AIS recovery. Using a rat model of middle cerebral artery occlusion (MCAO) and in vitro neurovascular unit (NVU) models, we found that IA-SCMI significantly improved neurological defects, alleviated brain damage, and enhanced cerebral blood flow compared to cooling or $MgSO_4$ alone. These effects were primarily driven by the regulation of $Ca^{2+}$ homeostasis across the NVU.
Introduction
Ischemic stroke occurs when a blood clot blocks a cerebral artery. While restoring blood flow (reperfusion) is critical, it often triggers "reperfusion injury," where oxidative stress and massive calcium ($Ca^{2+}$) overload lead to widespread cell death. Therapeutic hypothermia is a potent neuroprotector, but systemic cooling carries risks like shivering and arrhythmias. Localized cooling via intra-arterial saline infusion (IA-SCSI) is safer but limited by cold-induced microvascular contraction, which can paradoxically reduce blood flow.
This research investigates whether using $MgSO_4$—a known calcium antagonist—as the cooling medium (IA-SCMI) can overcome these limitations. The study explores the synergistic effects of physical cooling and pharmacological calcium regulation across the entire neurovascular unit (NVU).
Methods
The study employed a 2-hour middle cerebral artery occlusion (MCAO) model in male Sprague-Dawley rats. Upon reperfusion, rats received a 20-minute intra-arterial infusion of either room-temperature saline, room-temperature $MgSO_4$, chilled saline ($4^\circ\text{C}$), or chilled $MgSO_4$ (IA-SCMI).
To validate the cooling technique, temperatures were monitored in the rectum, contralateral/ipsilateral striatum, and cortex. Behavioral recovery was assessed over 14 days using mNSS, rotarod, and adhesive removal tests. In vitro experiments using neurons (HT22), endothelial cells (bEnd.3), and primary pericytes subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) were used to investigate cellular mechanisms, specifically $Ca^{2+}$ and ROS levels.
Results
Enhanced Neurological Recovery
Rats treated with IA-SCMI demonstrated superior functional recovery. Behavioral tests showed significant improvements in motor coordination and sensory-motor integration compared to all other treatment groups.
Protection of the Neurovascular Unit
IA-SCMI was the most effective at reducing infarct volume and preventing blood-brain barrier (BBB) leakage. A key finding was the role of pericytes: while cooling alone activates TRPM8 channels causing pericyte contraction and reduced blood flow, the addition of $Mg^{2+}$ blocks this influx, maintaining microvascular patency and enhancing cerebral blood flow (CBF).
Cellular Mechanism: Calcium Homeostasis
In vitro results confirmed that the combination of hypothermia ($32^\circ\text{C}$) and $MgSO_4$ ($10\text{ mM}$) provided maximum protection. This synergy effectively suppressed the "calcium storm" and ROS production across neurons, endothelial cells, and pericytes, stabilizing the entire NVU.
Discussion and Conclusion
The study demonstrates that IA-SCMI is a superior approach to standard cooling, offering a "two-birds-one-stone" solution by combining physical neuroprotection with biochemical calcium antagonism. By protecting the entire NVU rather than just neurons, this method addresses the critical issue of microcirculatory failure during reperfusion.
Future work must address the species gap between rats and humans and the technical complexities of integrating intra-arterial infusion into clinical thrombectomy workflows. Nevertheless, $MgSO_4$ represents a promising hypothermia infusion solution to facilitate neurological recovery in AIS patients.
Summary updated